Oxaliplatin in Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Patients must have histologically confirmed hepatocellular carcinoma * Patients must have measurable disease by CT scan * Patients with unresectable, recurrent or metastatic disease may be chemonaive or may be previously treated by chemotherapy. * The period of washout of prior chemotherapy must be greater than 4 weeks from date of randomization. The prior chemotherapy should not include platinum compounds. * WHO performance status: 0 to 2 * Patients must have adequate organ and marrow function as defined below: * Leukocytes : ≥ 3,000/μl * Absolute neutrophil count :≥ 1,500/μl * Platelets : ≥ 80,000/μl * Total bilirubin : \< 3.0g/dl * ASAT/ALAT : ≤ 3 times the upper normal limits of the institute * Creatinine : \< 120μmol/l * Patients with no evidence of clinically significant neuropathy. Exclusion Criteria: * Documented allergy to platinum compound or to others study's drugs * Pregnant or lactating women or women of childbearing potential (e.g. not using adequate contraception) * Hematological disorder or malignancies * Metastasis to central nervous system * Other serious illness or medical conditions: * Active infectious disease * Congestive heart failure, or angina pectoris. Previous history of myocardial infarction within 1 year from study entry; uncontrolled hypertension or arrhythmia. * Concurrent treatment with any other anticancer therapy * Concurrent treatment with other experimental drugs. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.